|
1
|
Mendenhall WM, Zlotecki RA, Scarborough
MT, Gibbs CP and Mendenhall NP: Giant cell tumor of bone. Am J Clin
Oncol. 29:96–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gamberi G, Serra M, Ragazzini P, Magagnoli
G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci
P and Benassi MS: Identification of markers of possible prognostic
value in 57 giant cell tumors of bone. Oncol Rep. 10:351–356.
2003.PubMed/NCBI
|
|
3
|
Trieb K, Bitzan P, Lang S, Dominkus M and
Kotz R: Recurrence of curetted and bone-grafted giant-cell tumours
with and without adjuvant phenol therapy. Eur J Surg Oncol.
27:200–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Campanacci M, Baldini N, Boriani S and
Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am.
69:106–114. 1987.PubMed/NCBI
|
|
5
|
Tse LF, Wong KC, Kumta SM, Huang L, Chow
TC and Griffith JF: Bisphosphonates reduce local recurrence in
extremity giant cell tumor of bone: A case-control study. Bone.
42:68–73. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gibbs CP, Lewis VO and Peabody T: Beyond
bone grafting: Techniques in the surgical management of benign bone
tumors. Instr Course Lect. 54:497–503. 2005.PubMed/NCBI
|
|
7
|
Zheng MH, Robbins P, Xu J, Huang L, Wood
DJ and Papadimitriou JM: The histogenesis of giant cell tumour of
bone: A model of interaction between neoplastic cells and
osteoclasts. Histol Histopathol. 16:297–307. 2001.PubMed/NCBI
|
|
8
|
Hopkins DR, Keles S and Greenspan DS: The
bone morphogenetic protein 1/Tolloid-like metalloproteinases.
Matrix Biol. 26:508–523. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Senta H, Park H, Bergeron E, Drevelle O,
Fong D, Leblanc E, Cabana F, Roux S, Grenier G and Faucheux N: Cell
responses to bone morphogenetic proteins and peptides derived from
them: Biomedical applications and limitations. Cytokine Growth
Factor Rev. 20:213–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh A and Morris RJ: The Yin and Yang of
bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev.
21:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barboza E, Caúla A and Machado F:
Potential of recombinant human bone morphogenetic protein-2 in bone
regeneration. Implant Dent. 8:360–367. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hogan BL: Bone morphogenetic proteins:
Multifunctional regulators of vertebrate development. Genes Dev.
10:1580–1594. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen A, Wang D, Liu X, He S, Yu Z and Wang
J: Inhibitory effect of BMP-2 on the proliferation of breast cancer
cells. Mol Med Rep. 6:615–620. 2012.PubMed/NCBI
|
|
14
|
Ye S, Park BH, Song KJ, Kim JR, Jang KY,
Park HS, Bae JS, Brochmann EJ, Wang JC, Murray SS and Lee KB: In
vivo inhibition of bone morphogenetic protein-2 on breast cancer
cell growth. Spine (Phila Pa 1976). 38:E143–E150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Langenfeld EM, Kong Y and Langenfeld J:
Bone morphogenetic protein 2 stimulation of tumor growth involves
the activation of Smad-1/5. Oncogene. 25:685–692. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kokorina NA, Lewis JS Jr, Zakharkin SO,
Krebsbach PH and Nussenbaum B: rhBMP-2 has adverse effects on human
oral carcinoma cell lines in vivo. Laryngoscope. 122:95–102. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Molina CA, Sarabia-Estrada R, Gokaslan ZL,
Witham TF, Bydon A, Wolinsky JP and Sciubba DM: Delayed onset of
paralysis and slowed tumor growth following in situ placement of
recombinant human bone morphogenetic protein 2 within spine tumors
in a rat model of metastatic breast cancer. J Neurosurg Spine.
16:365–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haÿ E, Lemonnier J, Fromigué O, Guénou H
and Marie PJ: Bone morphogenetic protein receptor IB signaling
mediates apoptosis independently of differentiation in osteoblastic
cells. J Biol Chem. 279:1650–1658. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kimura N, Matsuo R, Shibuya H, Nakashima K
and Taga T: BMP2-induced apoptosis is mediated by activation of the
TAK1-p38 kinase pathway that is negatively regulated by Smad6. J
Biol Chem. 275:17647–17652. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee KS, Hong SH and Bae SC: Both the Smad
and p38 MAPK pathways play a crucial role in Runx2 expression
following induction by transforming growth factor-beta and bone
morphogenetic protein. Oncogene. 21:7156–7163. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moustakas A and Heldin CH: Non-Smad
TGF-beta signals. J Cell Sci. 118:3573–3584. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guicheux J, Lemonnier J, Ghayor C, Suzuki
A, Palmer G and Caverzasio J: Activation of p38 mitogen-activated
protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their
implication in the stimulation of osteoblastic cell
differentiation. J Bone Miner Res. 18:2060–2068. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang L, Teng XY, Cheng YY, Lee KM and
Kumta SM: Expression of preosteoblast markers and Cbfa-1 and
Osterix gene transcripts in stromal tumour cells of giant cell
tumour of bone. Bone. 34:393–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kudo N, Ogose A, Ariizumi T, Kawashima H,
Hotta T, Hatano H, Morita T, Nagata M, Siki Y, Kawai A, et al:
Expression of bone morphogenetic proteins in giant cell tumor of
bone. Anticancer Res. 29:2219–2225. 2009.PubMed/NCBI
|
|
25
|
Su YP, Chen WM and Chen TH: Giant-cell
tumors of bone: An analysis of 87 cases. Int Orthop. 28:239–243.
2004.PubMed/NCBI
|
|
26
|
Saiz P, Virkus W, Piasecki P, Templeton A,
Shott S and Gitelis S: Results of giant cell tumor of bone treated
with intralesional excision. Clin Orthop Related Res. 424:221–226.
2004. View Article : Google Scholar
|
|
27
|
Ward WG Sr and Li G: Customized treatment
algorithm for giant cell tumor of bone: Report of a series. Clin
Orthop Relat Res. 397:259–270. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Turcotte RE, Wunder JS, Isler MH, Schachar
N, Masri BA, Moreau G and Davis AM: Canadian Sarcoma Group: Giant
cell tumor of bone. Giant cell tumor of long bone: A Canadian
sarcoma group study. Clin Orthop Relat Res. 397:248–258. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kleeff J, Maruyama H, Ishiwata T, Sawhney
H, Friess H, Büchler MW and Korc M: Bone morphogenetic protein 2
exerts diverse effects on cell growth in vitro and is expressed in
human pancreatic cancer in vivo. Gastroenterology. 116:1202–1216.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ide H, Yoshida T, Matsumoto N, Aoki K,
Osada Y, Sugimura T and Terada M: Growth regulation of human
prostate cancer cells by bone morphogenetic protein-2. Cancer Res.
57:5022–5027. 1997.PubMed/NCBI
|
|
31
|
Beck SE, Jung BH, Fiorino A, Gomez J,
Rosario ED, Cabrera BL, Huang SC, Chow JY and Carethers JM: Bone
morphogenetic protein signaling and growth suppression in colon
cancer. Am J Physiol Gastrointest Liver Physiol. 291:G135–G145.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wen XZ, Miyake S, Akiyama Y and Yuasa Y:
BMP-2 modulates the proliferation and differentiation of normal and
cancerous gastric cells. Biochem Biophys Res Commun. 316:100–106.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brubaker KD, Corey E, Brown LG and
Vessella RL: Bone morphogenetic protein signaling in prostate
cancer cell lines. J Cell Biochem. 91:151–160. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pouliot F, Blais A and Labrie C:
Overexpression of a dominant negative type II bone morphogenetic
protein receptor inhibits the growth of human breast cancer cells.
Cancer Res. 63:277–281. 2003.PubMed/NCBI
|
